Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Twist Bioscience Corporation, a leader in the Pharmaceutical Preparation Manufacturing industry, is headquartered in the United States. Founded in 2013, the company has rapidly established itself as a pioneer in synthetic DNA production, catering to diverse sectors including biotechnology, pharmaceuticals, and agriculture.
Twist Bioscience's innovative approach to DNA synthesis allows for high-throughput, cost-effective solutions that are unique in the market. Their core products include synthetic genes, gene fragments, and other DNA-based tools, which are essential for research and development in various scientific fields.
With a strong market position, Twist Bioscience has achieved significant milestones, including partnerships with major pharmaceutical companies and advancements in gene therapy applications. Their commitment to quality and efficiency continues to drive their success in the rapidly evolving biotechnology landscape.
-14 vs industry average
Twist Bioscience Corporation’s score of 28 is lower than 40% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Twist Bioscience Corporation, a US-based pharmaceutical preparation manufacturing company, reported its Scope 1 emissions for 2024 as 7,000 kg CO2e and its Scope 2 emissions as 3,000,000 kg CO2e. The company has not disclosed Scope 3 emissions data. Twist Bioscience is committed to climate action, with a near-term Science Based Target initiative (SBTi) target status of 'Committed'. This commitment indicates that Twist Bioscience has pledged to set science-based emissions reduction targets. The company has not yet set long-term or net-zero targets.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Twist Bioscience Corporation’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more